A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
Participants will receive one insulin icodec dose, which will be administered in the morning
of the day of dosing.
The study will last for about 8 weeks. Participants will have 8 visits with the study doctor
in the clinical research unit.
Insulin icodec will be injected into a skin fold with a small needle (subcutaneous
application) using a pen injector prefilled with a volume of 3 mL (about a spoonful).
Participants must not participate if they meet certain conditions called exclusion criteria,
such as an age of below 18 years or above 70 years, if participants are over- or underweight,
using certain medicines, or have serious health conditions (other than impaired liver
function ).
Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the
study period.